Monoclonal Antibody Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the monoclonal antibody market looks promising with opportunities in hospitals and research institutes. The global monoclonal antibody market is expected to grow with a CAGR of 5%-7% from 2020 to 2025. The major drivers for this market are increasing R&D activities in genomics and rising adoption of technologically advanced genetic platforms.
A total of XX figures / charts and XX tables are provided in this more than 150-pages report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global monoclonal antibody market report, please download the report brochure.
In this market, in-vivo is the largest production type of monoclonal antibody, whereas hospital is the largest end use. Growth in various segments of the monoclonal antibody market is given below:
The study includes trends and forecast for the global monoclonal antibody market by source type, production type, indication, end use, and region as follows:
By Source Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Murine
Chimeric
Humanized
Human
By Production Type [Value ($ Million) shipment analysis for 2014 – 2025]:
In-Vivo
In-Vitro
By Indication [Value ($ Million) shipment analysis for 2014 – 2025]:
Cancer
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Microbial Diseases
Others
By End Use [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals
Research Institutes
Others
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North America
United States
Canada
Mexico
Europe
United Kingdom
Spain
Germany
France
Asia Pacific
China
India
Japan
The Rest of the World
Brazil
Some of the monoclonal antibodies model companies profiled in this report include Novartis, Pfizer, GlaxoSmithKline, Thermo Fisher Scientific, Abbott, Merck, Roche, and Biogen.
Lucintel forecasts that In-vivo segment will remain the largest production type segment over the forecast period due to its cost effectiveness and high concentration of mAbs (monoclonal antibodies) obtained through this method.
Within this market, hospitals will remain the largest end use segment over the forecast period due to the increasing incidence of chronic conditions fueling treatment rate, rising healthcare expenditure level, and awareness level amongst the patient population regarding treatment alternatives.
North America will remain the largest region over the forecast period due to the presence of a large number of pharmaceutical and biotechnology companies in the region, the presence of a well-established healthcare market, and government support in infection control & management..
Features of the Global Monoclonal Antibody Market
Q.1 What are some of the most promising potential, high-growth opportunities for the global monoclonal antibody market by source type (murine, chimeric, humanized, and human), production type (In-vivo and In-vitro), indication (cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others), end use (hospitals, research institutes, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global monoclonal antibody market?
Q.5 What are the business risks and threats to the global monoclonal antibody market?
Q.6 What are the emerging trends in this monoclonal antibody market and the reasons behind them?
Q.7 What are some changing demands of customers in this monoclonal antibody market?
Q.8 What are the new developments in this monoclonal antibody market? Which companies are leading these developments?
Q.9 Who are the major players in this monoclonal antibody market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this monoclonal antibody market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global monoclonal antibody market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Source Type Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Source Type (Murine, Chimeric, Humanized, and Human), Production Type (In-Vivo and In-Vitro), Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others), and End Use (Hospitals, Research Institutes, and Others)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the monoclonal antibody market looks promising with opportunities in hospitals and research institutes. The global monoclonal antibody market is expected to grow with a CAGR of 5%-7% from 2020 to 2025. The major drivers for this market are increasing R&D activities in genomics and rising adoption of technologically advanced genetic platforms.
A total of XX figures / charts and XX tables are provided in this more than 150-pages report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global monoclonal antibody market report, please download the report brochure.
In this market, in-vivo is the largest production type of monoclonal antibody, whereas hospital is the largest end use. Growth in various segments of the monoclonal antibody market is given below:
The study includes trends and forecast for the global monoclonal antibody market by source type, production type, indication, end use, and region as follows:
By Source Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Murine
Chimeric
Humanized
Human
By Production Type [Value ($ Million) shipment analysis for 2014 – 2025]:
In-Vivo
In-Vitro
By Indication [Value ($ Million) shipment analysis for 2014 – 2025]:
Cancer
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Microbial Diseases
Others
By End Use [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals
Research Institutes
Others
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North America
United States
Canada
Mexico
Europe
United Kingdom
Spain
Germany
France
Asia Pacific
China
India
Japan
The Rest of the World
Brazil
Some of the monoclonal antibodies model companies profiled in this report include Novartis, Pfizer, GlaxoSmithKline, Thermo Fisher Scientific, Abbott, Merck, Roche, and Biogen.
Lucintel forecasts that In-vivo segment will remain the largest production type segment over the forecast period due to its cost effectiveness and high concentration of mAbs (monoclonal antibodies) obtained through this method.
Within this market, hospitals will remain the largest end use segment over the forecast period due to the increasing incidence of chronic conditions fueling treatment rate, rising healthcare expenditure level, and awareness level amongst the patient population regarding treatment alternatives.
North America will remain the largest region over the forecast period due to the presence of a large number of pharmaceutical and biotechnology companies in the region, the presence of a well-established healthcare market, and government support in infection control & management..
Features of the Global Monoclonal Antibody Market
- Market Size Estimates: Global monoclonal antibody market size estimation in terms of value ($M) shipment.
- Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
- Segmentation Analysis: Global monoclonal antibody market size by various segments, such as source type, production type, indication, and end use in terms of value.
- Regional Analysis: Global monoclonal antibody market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different source type, production type, indication, end use, and region for the global monoclonal antibody market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global monoclonal antibody market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
Q.1 What are some of the most promising potential, high-growth opportunities for the global monoclonal antibody market by source type (murine, chimeric, humanized, and human), production type (In-vivo and In-vitro), indication (cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others), end use (hospitals, research institutes, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global monoclonal antibody market?
Q.5 What are the business risks and threats to the global monoclonal antibody market?
Q.6 What are the emerging trends in this monoclonal antibody market and the reasons behind them?
Q.7 What are some changing demands of customers in this monoclonal antibody market?
Q.8 What are the new developments in this monoclonal antibody market? Which companies are leading these developments?
Q.9 Who are the major players in this monoclonal antibody market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this monoclonal antibody market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global monoclonal antibody market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Source Type Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Source Type (Murine, Chimeric, Humanized, and Human), Production Type (In-Vivo and In-Vitro), Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others), and End Use (Hospitals, Research Institutes, and Others)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Monoclonal Antibody Market Trends and Forecast
3.3: Global Monoclonal Antibody Market by Source Type
3.3.1: Murine
3.3.2: Chimeric
3.3.3: Humanized
3.3.4: Human
3.4: Global Monoclonal Antibody Market by Production Type
3.4.1: In-Viv
3.4.2: In-Vitr
3.5: Global Monoclonal Antibody Market by Indication
3.5.1: Cancer
3.5.2: Autoimmune Diseases
3.5.3: Inflammatory Diseases
3.5.4: Infectious Diseases
3.5.5: Microbial Diseases
3.5.6: Others
3.6: Global Monoclonal Antibody Market by End Use
3.6.1: Hospitals
3.6.2: Research Institutes
3.6.3: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Monoclonal Antibody Market by Region
4.2: North American Monoclonal Antibody Market
4.2.1: Market by Source Type: Murine, Chimeric, Humanized, and Human
4.2.2: Market by Production Type: In-Vivo and In-Vitro
4.2.3: Market by Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others
4.2.4: Market by End Use: Hospitals, Research Institutes, and Others
4.2.5: The United States Monoclonal Antibody Market
4.2.6: The Canadian Monoclonal Antibody Market
4.2.7: The Mexican Monoclonal Antibody Market
4.3: European Monoclonal Antibody Market
4.3.1: Market by Source Type: Murine, Chimeric, Humanized, and Human
4.3.2: Market by Production Type: In-Vivo and In-Vitro
4.3.3: Market by Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others
4.3.4: Market by End Use: Hospitals, Research Institutes, and Others
4.3.5: The United Kingdom Monoclonal Antibody Market
4.3.6: The Spanish Monoclonal Antibody Market
4.3.7: The German Monoclonal Antibody Market
4.3.8: The French Monoclonal Antibody Market
4.4: APAC Monoclonal Antibody Market
4.4.1: Market by Source Type: Murine, Chimeric, Humanized, and Human
4.4.2: Market by Production Type: In-Vivo and In-Vitro
4.4.3: Market by Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others
4.4.4: Market by End Use: Hospitals, Research Institutes, and Others
4.4.5: The Chinese Monoclonal Antibody Market
4.4.6: The Indian Monoclonal Antibody Market
4.4.7: The Japanese Monoclonal Antibody Market
4.5: ROW Monoclonal Antibody Market
4.5.1: Market by Source Type: Murine, Chimeric, Humanized, and Human
4.5.2: Market by Production Type: In-Vivo and In-Vitro
4.5.3: Market by Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others
4.5.4: Market by End Use: Hospitals, Research Institutes, and Others
4.5.5: Brazilian Monoclonal Antibody Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Source Type Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Monoclonal Antibody Market by Source Type
7.1.2: Growth Opportunities for the Global Monoclonal Antibody Market by Production Type
7.1.3: Growth Opportunities for the Global Monoclonal Antibody Market by Indication
7.1.4: Growth Opportunities for the Global Monoclonal Antibody Market by End User
7.1.5: Growth Opportunities for the Global Monoclonal Antibody Market by Region
7.2: Emerging Trends in the Global Monoclonal Antibody Market
7.3: Strategic Analysis
7.3.1: New Source Type Development
7.3.2: Capacity Expansion of the Global Monoclonal Antibody Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Monoclonal Antibodies Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Merck & Co.
8.2: Novartis AG
8.3: Pfizer, Inc.
8.4: GlaxoSmithKline plc
8.5: Abbott
8.6: AstraZeneca
8.7: Therm Fisher Scientific
8.8: F. Hoffmann-La Roche Ltd
8.9: Biogen Inc.
8.10: Bayer Inc.
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Monoclonal Antibody Market Trends and Forecast
3.3: Global Monoclonal Antibody Market by Source Type
3.3.1: Murine
3.3.2: Chimeric
3.3.3: Humanized
3.3.4: Human
3.4: Global Monoclonal Antibody Market by Production Type
3.4.1: In-Viv
3.4.2: In-Vitr
3.5: Global Monoclonal Antibody Market by Indication
3.5.1: Cancer
3.5.2: Autoimmune Diseases
3.5.3: Inflammatory Diseases
3.5.4: Infectious Diseases
3.5.5: Microbial Diseases
3.5.6: Others
3.6: Global Monoclonal Antibody Market by End Use
3.6.1: Hospitals
3.6.2: Research Institutes
3.6.3: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Monoclonal Antibody Market by Region
4.2: North American Monoclonal Antibody Market
4.2.1: Market by Source Type: Murine, Chimeric, Humanized, and Human
4.2.2: Market by Production Type: In-Vivo and In-Vitro
4.2.3: Market by Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others
4.2.4: Market by End Use: Hospitals, Research Institutes, and Others
4.2.5: The United States Monoclonal Antibody Market
4.2.6: The Canadian Monoclonal Antibody Market
4.2.7: The Mexican Monoclonal Antibody Market
4.3: European Monoclonal Antibody Market
4.3.1: Market by Source Type: Murine, Chimeric, Humanized, and Human
4.3.2: Market by Production Type: In-Vivo and In-Vitro
4.3.3: Market by Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others
4.3.4: Market by End Use: Hospitals, Research Institutes, and Others
4.3.5: The United Kingdom Monoclonal Antibody Market
4.3.6: The Spanish Monoclonal Antibody Market
4.3.7: The German Monoclonal Antibody Market
4.3.8: The French Monoclonal Antibody Market
4.4: APAC Monoclonal Antibody Market
4.4.1: Market by Source Type: Murine, Chimeric, Humanized, and Human
4.4.2: Market by Production Type: In-Vivo and In-Vitro
4.4.3: Market by Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others
4.4.4: Market by End Use: Hospitals, Research Institutes, and Others
4.4.5: The Chinese Monoclonal Antibody Market
4.4.6: The Indian Monoclonal Antibody Market
4.4.7: The Japanese Monoclonal Antibody Market
4.5: ROW Monoclonal Antibody Market
4.5.1: Market by Source Type: Murine, Chimeric, Humanized, and Human
4.5.2: Market by Production Type: In-Vivo and In-Vitro
4.5.3: Market by Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others
4.5.4: Market by End Use: Hospitals, Research Institutes, and Others
4.5.5: Brazilian Monoclonal Antibody Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Source Type Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Monoclonal Antibody Market by Source Type
7.1.2: Growth Opportunities for the Global Monoclonal Antibody Market by Production Type
7.1.3: Growth Opportunities for the Global Monoclonal Antibody Market by Indication
7.1.4: Growth Opportunities for the Global Monoclonal Antibody Market by End User
7.1.5: Growth Opportunities for the Global Monoclonal Antibody Market by Region
7.2: Emerging Trends in the Global Monoclonal Antibody Market
7.3: Strategic Analysis
7.3.1: New Source Type Development
7.3.2: Capacity Expansion of the Global Monoclonal Antibody Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Monoclonal Antibodies Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Merck & Co.
8.2: Novartis AG
8.3: Pfizer, Inc.
8.4: GlaxoSmithKline plc
8.5: Abbott
8.6: AstraZeneca
8.7: Therm Fisher Scientific
8.8: F. Hoffmann-La Roche Ltd
8.9: Biogen Inc.
8.10: Bayer Inc.
